ProSieben puts online drugstore Windstar Medical up for sale – sources

By Arno Schuetze and Klaus Lauer

FRANKFURT, Sept 30 (Reuters)German TV broadcaster ProSiebenSat.1PSMGn.DE has put its online drugstore Windstar Medical up for sale as it streamlines its technology investments, people close to the matter said.

The profitable retailer of over-the-counter drugs could be valued at around 250 million euros ($293 million), including debt, in a potential deal, the people said.

Non-binding offers for the unit are due shortly with mostly private equity groups expected to show interest in the start-up with some 100 employees, they said.

ProSieben said it announced in March 2020 that it would examine all existing investments to see whether there are clear synergies with its core business, adding that it would assess in each case whether it is the best owner for individual companies.

ProSieben, under new management, is looking to raise money from asset sales after the reign of former CEO Max Conze ended amid boardroom acrimony earlier this year and the coronavirus pandemic slashed advertising revenues at its core commercial television business by 40%.

New CEO Rainer Beaujean is also having to contend with persistent takeover speculation after Italy’s Mediaset MS.MI amassed a 24.2% stake, while Czech investor Daniel Kretinsky and private equity firm KKR KKR.N have also built shareholdings.

Separately, ProSieben is exploring the possible sale of beauty products retailer Flaconi, which competes with larger peers Douglas, one of the people said.

ProSieben bought Windstar Medical in 2016 through its technology subsidiary NuCom.

Windstar Medical sells non-prescription healthcare products and has its own brands including SOS, GreenDoc and Vitalia and according to ProSieben’s 2019 annual report saw “significant growth”.

($1 = 0.8543 euros)

(Additional reporting by Douglas Busvine Editing by Thomas Seythal and Tomasz Janowski)

(([email protected]; +49 30220133648;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article